Avoro Capital Advisors LLC's Form 4 filing
Scribe Therapeutics, Inc. (SCTX) · filed Jul 28, 2026
- Accession no.
- 0000902664-26-003270
- Filed
- Jul 28, 2026, 9:30 PM ET
- Trade date
- Jul 24-28, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market purchases total $36.3M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Avoro Capital Advisors LLCCIK 0001633313 | Director, 10% Owner, Other: See Remarks |
| Aghazadeh BehzadCIK 0001701815 | Director, 10% Owner, Other: See Remarks |
| Avoro Ventures LLCCIK 0001879253 | Director, Other: See Remarks |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 24, 2026 | Common Stock, par value $0.0001 per share | PPurchaseAcquired | +2,333,333 | $15.00 | +$34,999,995 | 3,030,983 | Indirect | |
| Jul 24, 2026 | Common Stock, par value $0.0001 per share | PPurchaseAcquired | +50,000 | $22.31 | +$1,115,500 | 3,080,983 | Indirect | |
| Jul 28, 2026 | Common Stock, par value $0.0001 per share | PPurchaseAcquired | +7,905 | $18.25 | +$144,266.25 | 3,088,888 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.